J&J/Crucell deal might snag on bid issues

While J&J may consider lowering its bid for Crucell because of manufacturing issues, some Crucell shareholders are determined to hold out for more. Van Herk, the second largest Crucell shareholder, with a 10 percent stake in the company, has pushed for a €27.50 ($36.17) per share deal, although the company's stock currently trades 4.5 percent below J&J's current offer.

Crucell's South Korean plant suffered a microbiologic contamination last year, triggering a €23 million ($30.2 million) inventory loss. And although the plant should be reopened in February, the issues have some shareholders on edge, worried that J&J could lower or withdraw its current offer. These concerns have led the company to push shareholders to accept the current bid.

According to Reuters, if J&J can secure 80 percent to 95 percent of Crucell's stock, minority shareholders could be muscled out, leaving Van Herk in a potentially difficult position.

"It is simply a question of timing, that is why the share price is below the offer price,"  Exane BNP Paribas analyst Vincent Meunier told Reuters. "This is also a good reason to really tender their shares."

- check out Reuters' coverage

Suggested Articles

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.